Investment Rating - The report maintains an "Outperform" rating for the company [2] Core Insights - The company reported a revenue of 310 million yuan in 2024, a decrease of 9.1% year-on-year, and a net profit of 13 million yuan, down 71.0% year-on-year, which was below expectations [7] - In Q1 2025, the company achieved a revenue of 55 million yuan, an increase of 37.8% year-on-year, although it reported a net loss of 1 million yuan [7] - The company is expected to benefit from government policies aimed at promoting equipment updates and increasing technology spending, which could lead to a recovery in demand [7][10] Financial Data and Profit Forecast - The company’s total revenue is projected to be 342 million yuan in 2025, with a year-on-year growth rate of 10.2% [6] - The net profit forecast for 2025 is 43 million yuan, representing a significant increase of 230.5% compared to 2024 [6] - The company’s gross margin is expected to be 65.6% in 2025, slightly improving from 64.3% in Q1 2025 [6] Revenue Breakdown - In 2024, the company’s revenue from organic element analysis was 104 million yuan, down 23.0% year-on-year, while sample preparation revenue was 57 million yuan, down 18.7% [7] - The chromatography and spectroscopy segment generated 79 million yuan, with liquid chromatography instruments contributing 46 million yuan, an increase of 27.2% year-on-year [7] - The company’s international revenue reached 70 million yuan in 2024, up 12.2% year-on-year, driven by expanded overseas distribution channels [7] Strategic Initiatives - The company has been investing in automation and digitalization since 2014, enhancing its manufacturing capabilities [10] - The introduction of a digital core platform in 2024 is expected to support the production of customized non-standard components [10] - The report highlights the company’s proactive approach in recruiting high-quality talent during industry downturns to ensure long-term growth [7][10]